NUVO yields 1176.47% · ABBV yields 3.09%● Live data
📍 NUVO pulled ahead of the other in Year 1
Combined, NUVO + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NUVO + ABBV for your $10,000?
Holdco Nuvo Group D.G Ltd engages in the research, development, and marketing of medical devices for pregnancy monitoring in Israel, the United States, and internationally. It provides INVU platform, a remote pregnancy monitoring platform that provides expectant mothers with a self -administered wireless sensory band, which enables them and their obstetricians to monitor maternal and fetal heart rate, and maternal uterine activity at home and in the clinic from the 32nd week of pregnancy until the beginning of labor. The company's INVU platform includes a wireless sensory band with multi-modality technology to capture signals to enable the INVU platform; and a cloud computing environment that processes and analyzes data and transmits personalized reports on maternal and fetal health metrics to the expectant mother and her obstetrician through digital visualization tools. It has a collaboration with Royal Philips and Charité Universitätsmedizin Berlin. The company was formerly known as Nuvo Group Ltd. and changed its name to Holdco Nuvo Group D.G Ltd in May 2024. Holdco Nuvo Group D.G Ltd incorporated in 2006 and is headquartered in Tel Aviv, Israel. On August 22, 2024, Holdco Nuvo Group D.G Ltd filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Full NUVO Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.